Abstract
This chapter seeks to document advances and controversies in relation to mechanisms underlying the therapeutic and adverse effects of antipsychotic drugs. It focuses on findings for second-generation agents, with an emphasis on neuroimaging studies in living patients; yet it is mindful of what we have learned and have still to learn from their first-generation counterparts. Thereafter, it considers putative "third-generation" agents, and then considers novel mechanisms and possible future developments.
| Original language | English |
|---|---|
| Title of host publication | Schizophrenia |
| Subtitle of host publication | Third Edition |
| Publisher | Wiley Blackwell |
| Pages | 483-514 |
| Number of pages | 32 |
| ISBN (Print) | 9781405176972 |
| DOIs | |
| Publication status | Published - 8 Mar 2011 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
UCC Futures
- Future Ageing and Brain Science
Keywords
- Adverse effects
- Antipsychotics
- Dopamine
- Glutamate
- PET
- Psychological mechanisms
- Serotonin
- SPECT
- Therapeutic efficacy
Fingerprint
Dive into the research topics of 'Pharmacology and Neuroscience of Antipsychotic Drugs'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver